The announcement of specific timelines for interim and final overall survival data for Dordaviprone positions Chimerix in a positive light, potentially raising investor expectations and confidence in the company's pipeline. This could lead to increased stock demand in anticipation of positive results, thus positively impacting the stock price in the short term.